Jeffrey S. Parkin

Array ( [id] => 1388112 [patent_doc_number] => 06544752 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-04-08 [patent_title] => 'Anigenically-marked non-infectious retrovirus-like particles' [patent_app_type] => B1 [patent_app_number] => 09/636223 [patent_app_country] => US [patent_app_date] => 2000-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 9586 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 246 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/544/06544752.pdf [firstpage_image] =>[orig_patent_app_number] => 09636223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1493359 [patent_doc_number] => 06342228 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-01-29 [patent_title] => 'Diagnostic kits comprising genetically engineered human immunodeficiency virus-like particles containing heterologous antigenic markers' [patent_app_type] => B1 [patent_app_number] => 09/636805 [patent_app_country] => US [patent_app_date] => 2000-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 9595 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 195 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/342/06342228.pdf [firstpage_image] =>[orig_patent_app_number] => 09636805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1414415 [patent_doc_number] => 06518030 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-02-11 [patent_title] => 'Antigentically-marked non-infectious retrovirus-like particles' [patent_app_type] => B1 [patent_app_number] => 09/635754 [patent_app_country] => US [patent_app_date] => 2000-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 9585 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 265 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/518/06518030.pdf [firstpage_image] =>[orig_patent_app_number] => 09635754 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4609757 [patent_doc_number] => 07994278 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2011-08-09 [patent_title] => 'Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)' [patent_app_type] => utility [patent_app_number] => 09/632831 [patent_app_country] => US [patent_app_date] => 2000-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 70 [patent_no_of_words] => 57284 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/994/07994278.pdf [firstpage_image] =>[orig_patent_app_number] => 09632831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 701135 [patent_doc_number] => 07063849 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2006-06-20 [patent_title] => 'Use of HIV-1 gp120 and gp160 proteins modified in the v3 loop for the preparation of vaccine compositions and formulations containing the same' [patent_app_type] => utility [patent_app_number] => 09/632806 [patent_app_country] => US [patent_app_date] => 2000-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4958 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/063/07063849.pdf [firstpage_image] =>[orig_patent_app_number] => 09632806 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1387538 [patent_doc_number] => 06541003 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-04-01 [patent_title] => 'Conditionally controlled, attenuated HIV vaccine' [patent_app_type] => B1 [patent_app_number] => 09/624964 [patent_app_country] => US [patent_app_date] => 2000-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 6201 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/541/06541003.pdf [firstpage_image] =>[orig_patent_app_number] => 09624964 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 675538 [patent_doc_number] => 07087375 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2006-08-08 [patent_title] => 'Method for determining the mechanism of HIV RT inhibitors' [patent_app_type] => utility [patent_app_number] => 09/599877 [patent_app_country] => US [patent_app_date] => 2000-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10137 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 232 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/087/07087375.pdf [firstpage_image] =>[orig_patent_app_number] => 09599877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1213558 [patent_doc_number] => 06710173 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-03-23 [patent_title] => 'Stabilized viral envelope proteins and uses thereof' [patent_app_type] => B1 [patent_app_number] => 09/602864 [patent_app_country] => US [patent_app_date] => 2000-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 15 [patent_no_of_words] => 22978 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/710/06710173.pdf [firstpage_image] =>[orig_patent_app_number] => 09602864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 916580 [patent_doc_number] => 07323174 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2008-01-29 [patent_title] => 'Modulation of immune response and methods based thereon' [patent_app_type] => utility [patent_app_number] => 09/591789 [patent_app_country] => US [patent_app_date] => 2000-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13229 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/323/07323174.pdf [firstpage_image] =>[orig_patent_app_number] => 09591789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 250545 [patent_doc_number] => 07582301 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2009-09-01 [patent_title] => 'Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides' [patent_app_type] => utility [patent_app_number] => 09/623533 [patent_app_country] => US [patent_app_date] => 2000-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31677 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/582/07582301.pdf [firstpage_image] =>[orig_patent_app_number] => 09623533 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1179182 [patent_doc_number] => 06737066 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-05-18 [patent_title] => 'HIV immunogenic compositions and methods' [patent_app_type] => B1 [patent_app_number] => 09/565906 [patent_app_country] => US [patent_app_date] => 2000-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 18 [patent_no_of_words] => 10291 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/737/06737066.pdf [firstpage_image] =>[orig_patent_app_number] => 09565906 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6570933 [patent_doc_number] => 20020165364 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-11-07 [patent_title] => 'Fluorescent protein sensors for detection of analytes' [patent_app_type] => new [patent_app_number] => 09/554000 [patent_app_country] => US [patent_app_date] => 2000-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 13821 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0165/20020165364.pdf [firstpage_image] =>[orig_patent_app_number] => 09554000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 641494 [patent_doc_number] => 07122193 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2006-10-17 [patent_title] => 'Retro peptides, antibodies thereto and their uses for vaccination and in vitro diagnosis' [patent_app_type] => utility [patent_app_number] => 09/549186 [patent_app_country] => US [patent_app_date] => 2000-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 22 [patent_no_of_words] => 34452 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/122/07122193.pdf [firstpage_image] =>[orig_patent_app_number] => 09549186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1331210 [patent_doc_number] => 06596477 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-07-22 [patent_title] => 'Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid A' [patent_app_type] => B1 [patent_app_number] => 09/536668 [patent_app_country] => US [patent_app_date] => 2000-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 20120 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/596/06596477.pdf [firstpage_image] =>[orig_patent_app_number] => 09536668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1282796 [patent_doc_number] => 06638514 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-10-28 [patent_title] => 'Multivalent dengue virus vaccine' [patent_app_type] => B1 [patent_app_number] => 09/535117 [patent_app_country] => US [patent_app_date] => 2000-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 19 [patent_no_of_words] => 20357 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/638/06638514.pdf [firstpage_image] =>[orig_patent_app_number] => 09535117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1392193 [patent_doc_number] => 06537557 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-03-25 [patent_title] => 'Attenuated dengue-4 virus vaccine' [patent_app_type] => B1 [patent_app_number] => 09/534726 [patent_app_country] => US [patent_app_date] => 2000-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 19 [patent_no_of_words] => 20815 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/537/06537557.pdf [firstpage_image] =>[orig_patent_app_number] => 09534726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1412071 [patent_doc_number] => 06511667 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-01-28 [patent_title] => 'Attenuated dengue-2 virus vaccine' [patent_app_type] => B1 [patent_app_number] => 09/534725 [patent_app_country] => US [patent_app_date] => 2000-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 19 [patent_no_of_words] => 20884 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/511/06511667.pdf [firstpage_image] =>[orig_patent_app_number] => 09534725 [rel_patent_id] =>[rel_patent_doc_number] =>)